Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$57.02 USD

57.02
567,398

+0.73 (1.30%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $57.03 +0.01 (0.02%) 6:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Illumina (ILMN), Nashville Biosciences Partner With Amgen

Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.

Teladoc (TDOC) Boosts Revenue Guidance, Shares Jump 4.1%

Teladoc (TDOC) expects around $1 billion in revenues from its BetterHelp mental health business in 2022.

Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind

Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.

Abbott's (ABT) New Launch to Boost Blood Donation Experience

Abbott's (ABT) mixed reality offers donors an innovative, immersive digital experience while giving blood.

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

Investors are optimistic about SmileDirectClub (SDC) on continued strategic partnerships and expansion in the teledentistry space.

Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

LabCorp (LH) Oncology Arm Gains Traction, Margin Pressure Stays

In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.

QuidelOrtho (QDEL) Reports Solid Preliminary Q4 Revenues

QuidelOrtho's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.

Baxter (BAX) Plans to Form Standalone Kidney Care Company

Baxter (BAX) plans several strategic actions, including spin-off of Renal Care and Acute Therapies global business units into an independent, publicly traded company to simplify its operating model.

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Here's Why You Should Buy Cardinal Health (CAH) Stock Now

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

UnitedHealth's (UNH) Optum to Boost Northern Light's Efficiency

Per the deal, around 1,400 employees of Northern Light are likely to shift to UnitedHealth's (UNH) Optum this March.

Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up

Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.

Alcon (ALC) Gains From Innovation, Faces FX Challenges

Alcon's (ALC) Surgical franchise continues to lead the market with its portfolio of advanced technology, intraocular lenses, a substantial installed base of equipment and a growing consumable base.

AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.

Here's Why You Should Retain Ecolab (ECL) Stock for Now

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio (Revised)

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Bruker's (BRKR) New Tie-Up to Expand Its U.S. CRO Business

Bruker's (BRKR) latest partnership is expected to expand its CRO business in the United States, benefiting more biopharma and diagnostics companies using unbiased proteomics for decision-making.

Here's Why You Should Retain Stryker (SYK) Stock for Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.

Walgreens Boots (WBA) Q1 Earnings Top, Revenues View Up

The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.

HCA Healthcare (HCA) Unit in Talks to Buy Wise Health System

HCA Healthcare's (HCA) deal with Wise Health System is expected to boost its footprint and market share in Texas.

AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know

AMN Healthcare Services (AMN) closed the most recent trading day at $103.97, moving -1.92% from the previous trading session.